{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:42:01Z","timestamp":1758588121496,"version":"3.44.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.transproceed.2017.12.052","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T21:06:27Z","timestamp":1523653587000},"page":"869-872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of Juvenile Idiopathic Arthritis in ABO-incompatible Kidney Transplantation: A Case Report"],"prefix":"10.1016","volume":"50","author":[{"given":"S.","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2017.12.052_bib1","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1002\/art.10444","article-title":"Long-term outcome in patients with juvenile idiopathic arthritis","volume":"46","author":"Minden","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.transproceed.2017.12.052_bib2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2017.12.052_bib3","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","article-title":"A\u00a0randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate","volume":"50","author":"Gaspari","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.transproceed.2017.12.052_bib4","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","article-title":"Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate","volume":"50","author":"Ruperto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.transproceed.2017.12.052_bib5","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.transproceed.2017.12.052_bib6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3899\/jrheum.130690","article-title":"Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan","volume":"41","author":"Yokota","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.transproceed.2017.12.052_bib7","first-page":"61","article-title":"Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy","volume":"26","author":"Goldzweig","year":"2011","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.transproceed.2017.12.052_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00007890-200008270-00024","article-title":"Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation","volume":"70","author":"Ishida","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.12.052_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000355855","article-title":"Impact of the baseline anti-A\/B antibody titer on the clinical outcome in ABO-incompatible kidney transplantation","volume":"124","author":"Chung","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.transproceed.2017.12.052_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1399-3089.2006.00277.x","article-title":"Pinpoint targeted immunosuppression; anti-CD20\/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy","volume":"13","author":"Saito","year":"2006","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.transproceed.2017.12.052_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/msc.134","article-title":"A\u00a0survey of foot problems in juvenile idiopathic arthritis","volume":"6","author":"Hendry","year":"2008","journal-title":"Musculoskel Care"},{"key":"10.1016\/j.transproceed.2017.12.052_bib12","first-page":"943","article-title":"Efficacy of custom foot orthotics in improving pain and functional status in children with juvenile idiopathic arthritis: a randomized trial","volume":"32","author":"Powell","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.transproceed.2017.12.052_bib13","first-page":"154","article-title":"Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis","volume":"50","author":"Nakano","year":"1998","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.transproceed.2017.12.052_bib14","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2017.12.052_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/14397595.2013.854079","article-title":"Drug free remission\/low disease activity after cessation of tocilizumab (Actemura) monotherapy (DREAM) study","volume":"24","author":"Nishimoto","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.transproceed.2017.12.052_bib16","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10067-011-1720-7","article-title":"Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis","volume":"30","author":"Alexeeva","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.transproceed.2017.12.052_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/DDDT.S41645","article-title":"Rituximab for the treatment of rheumatoid arthritis: an update","volume":"27","author":"Mok","year":"2013","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.transproceed.2017.12.052_bib18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B\u00a0cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.transproceed.2017.12.052_bib19","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1093\/rheumatology\/keu297","article-title":"Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus","volume":"53","author":"Shimizu","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.transproceed.2017.12.052_bib20","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00431-006-0380-0","article-title":"Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus","volume":"166","author":"Tanaka","year":"2007","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.transproceed.2017.12.052_bib21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1567-5769(01)00008-X","article-title":"Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in\u00a0vitro","volume":"1","author":"Sakuma","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.transproceed.2017.12.052_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.transproceed.2004.12.140","article-title":"Predominant inhibition of interleukin-6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is affected and mitotic arrest takes place","volume":"37","author":"Lehle","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2017.12.052_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/art.39399","article-title":"Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.transproceed.2017.12.052_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/14397595.2015.1123211","article-title":"Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517309764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517309764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:31:39Z","timestamp":1758576699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134517309764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0041134517309764"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.12.052","relation":{},"ISSN":["0041-1345"],"issn-type":[{"type":"print","value":"0041-1345"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Juvenile Idiopathic Arthritis in ABO-incompatible Kidney Transplantation: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.12.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}